Despite this, SGLT-2 inhibitors continue to demonstrate significant cardiorenal benefits in advanced DKD, potentially due to their ability to suppress inflammation and fibrosis, improve oxidative stress, enhance EPO production, optimize mitochondrial energy supply, inhibit the SNS, and protect vascular endothelial cells. This evidence concerns the gene SLC5A2 and diabetic kidney disease.